Nature Reviews Cancer contents March 2017 Volume 17 Number 3 pp141-204

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
March 2017 Volume 17 Number 3		Advertisement
2015 2-year Impact Factor 34.244 Journal Metrics 2-year Median 27	In this issue Research Highlights Reviews Perspectives Also this month  Featured article: A chemical probe toolbox for dissecting the cancer epigenome Jake Shortt, Christopher J. Ott, Ricky W. Johnstone & James E. Bradner	Nature Insight Frontiers in Biology This year's Frontiers in Biology Insight features Reviews on how genomics is helping to uncover the peopling of the world, the interplay between morphogens and morphogenesis in determining organismal shape, the factors that influence the immune response to cancer, advances in single-cell genomics, and the effects of base modifications in messenger RNA.
Subscribe   Facebook   RSS   Recommend to library   Twitter
RESEARCH HIGHLIGHTS Top Tumour evolution: Epigenetic and genetic heterogeneity in metastasis p141 | doi:10.1038/nrc.2017.11 How similar are metastases to the primary tumour and other metastases in the same patient? And what does that tell us about the evolution of metastatic ability? Two papers investigated these questions in pancreatic ductal adenocarcinoma (PDAC). PDF Early detection: The algorithm will see you now p142 | doi:10.1038/nrc.2017.10 Esteva et al. have developed an artificial intelligence algorithm which recognises and classifies skin cancers as accurately as specialist clinicians, thereby automating diagnosis. PDF Tumorigenesis: Fitness penalties of aneuploidy p142 | doi:10.1038/nrc.2017.9 Sheltzer et al. find that single-chromosome gains can prevent tumorigenesis relative to genetically matched euploid cells, but that these aneuploid cells can evolve over time to have improved fitness. PDF Tumorigenesis: Extra! Extra! Read all about it! p143 | doi:10.1038/nrc.2017.12 Two papers demonstrate that centrosome amplification can cause cancer in mammals and that a PIDDosome–p53-dependent control mechanism acts to prevent cell proliferation in the presence of extra centrosomes. PDF Cancer JOBS of the week Postdoctoral Fellows: Cancer Genetics, Epigenetics and Biomarkers Baylor Scott & White Research Institute Director, UT Health San Antonio MD Anderson Cancer Center UT Health Science Center San Antonio Postdoctoral Fellow - Cancer Biology - Kong lab City of Hope Postdoctoral position: RNA, Stem Cell and Cancer Biology Lund University Tumor Immunology / Immunotherapy / Tumor Microenvironment in Pediatric Cancer Children's Cancer Research Institute; St. Anna Kinderkrebsforschung More Science jobs from Cancer EVENT 3rd World Congress on Cancer and Prevention Methods 05.04.17 Barcelona, Spain More science events from
REVIEWS		Top
Notch as a tumour suppressor Craig S. Nowell & Freddy Radtke p145 | doi:10.1038/nrc.2016.145 In this Review, Nowell and Radtke outline the accumulating evidence that Notch functions as a tumour suppressor in a range of cancers, and present potential mechanisms by which loss of Notch signalling could promote tumorigenesis. Abstract | Full Text | PDF
A chemical probe toolbox for dissecting the cancer epigenome Jake Shortt, Christopher J. Ott, Ricky W. Johnstone & James E. Bradner p160 | doi:10.1038/nrc.2016.148 This review summarizes the state of the art in chemical probes targeting molecular processes operating at the chromatin interface in cancer cells. It seeks to provide a chemical toolbox for use by scientists to dissect epigenetic vulnerabilities of tumour biology. Abstract | Full Text | PDF | Supplementary information
SUMO and the robustness of cancer Jacob-Sebastian Seeler & Anne Dejean p184 | doi:10.1038/nrc.2016.143 Sumoylation is an important mechanism in cellular responses to stress, and appears to be upregulated in many cancers. This Review argues that sumoylation protects the stability and functionality of otherwise easily misregulated gene expression programmes and signalling pathways of cancer cells. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer Carl A. K. Borrebaeck p199 | doi:10.1038/nrc.2016.153 This Opinion article focuses on the trends and progress being made in identifying protein biomarker signatures of clinical utility in cancer using, in particular, blood-based proteomics. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.